

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
KINTOR PHARMA'S TWO PHASE III CLINICAL TRIALS OF
PROXALUTAMIDE APPROVED BY NMPA FOR THE PROPOSED
TREATMENT OF COVID-19**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Kintor Pharma**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that it has received the approval from the National Medical Products Administration (“**NMPA**”) of China for two phase III clinical trials of proxalutamide (the “**Phase III Clinical Trials**”, each a “**Phase III Clinical Trial**”) for treating COVID-19 infections in China.

Both of the Phase III Clinical Trials are part of the multi-regional clinical trials (“**MRCT**”) globally. One of the Phase III Clinical Trials (NCT number: NCT04869228) will be conducted for the proposed treatment of mild or moderate male COVID-19 patients in countries and regions, including China, Brazil, Malaysia and the Philippines while the other Phase III Clinical Trial (NCT number: NCT05009732) will be conducted for the treatment of hospitalised COVID-19 patients in countries and regions, including the United States, China, South America (including Brazil), Europe and India.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

KINTOR PHARMACEUTICAL LIMITED

Dr. Youzhi Tong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 1 September 2021

As at the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purposes only*